Teri E. Klein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Teri E. Klein has a total of 327 co-authors. Here are the top co-authors by number of shared publications:
- Michelle Whirl‐Carrillo
Department of Biomedical Data Science Stanford University Stanford California USA
24 shared publications - Andrea Gaedigk
Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation Children’s Mercy Kansas City Kansas City Missouri USA
13 shared publications - Katrin Sangkuhl
Department of Biomedical Data Science Stanford University Stanford California USA
11 shared publications - Kelly E. Caudle
Department of Pharmacy and Pharmaceutical Sciences St Jude Children's Research Hospital Memphis Tennessee USA
11 shared publications - Russ Altman
Stanford University
9 shared publications - Roseann S. Gammal
Department of Pharmacy and Pharmaceutical Sciences St. Jude Children’s Research Hospital Memphis Tennessee USA
6 shared publications
Latest Publications
- Open Access
Global population frequencies of NAT2 star alleles observed in three large biobanks
NAT2 is an important pharmacogene which encodes the N-acetyltransferase 2 enzyme that is involved in the metabolism of multiple medications, and variants in this gene can affect patient response to these medications. CPIC has published a clinical guideline for prescribing hydralazine using NAT2 genotypes. Just prior to the guideline, updated NAT2 star allele numbering and definitions were released, differing somewhat from the historical nomenclature. Clinical pharmacogenomic testing panels often test for the most common star alleles, so knowledge of the most common updated NAT2 star alleles is critical for the implementation of the CPIC NAT2/hydralazine guideline. We first determine NAT2 diplotype frequencies from UK Biobank (UKBB) 200k phased genomes, then analyzed allele, diplotype, and phenotype population frequencies from the All of Us Research program, PennMedicine BioBank (PMBB) and UKBB 500k datasets. We found that analyzing NAT2 diplotypes from phased data provides critical information for algorithms designed to predict diplotypes from unphased data. We observed that NAT2*5 , *6 , and *4 were the most common star alleles in that order, and the top 11 most frequent NAT2 star alleles were the same across all biobanks. However, differences in star allele frequencies across biogeographical populations were observed. The largest difference led to a higher frequency of NAT2 poor metabolizer phenotypes as compared to rapid and intermediate metabolizer phenotypes in all global populations except in the EAS population, where NAT2 poor metabolizers were in the minority.
Open AccessGlobal population frequencies of NAT2 star alleles observed in three large biobanks
NAT2 is an important pharmacogene which encodes the N-acetyltransferase 2 enzyme that is involved in the metabolism of multiple medications, and variants in this gene can affect patient response to these medications. CPIC has published a clinical guideline for prescribing hydralazine using NAT2 genotypes. Just prior to the guideline, updated NAT2 star allele numbering and definitions were released, differing somewhat from the historical nomenclature. Clinical pharmacogenomic testing panels often test for the most common star alleles, so knowledge of the most common updated NAT2 star alleles is critical for the implementation of the CPIC NAT2/hydralazine guideline. We first determine NAT2 diplotype frequencies from UK Biobank (UKBB) 200k phased genomes, then analyzed allele, diplotype, and phenotype population frequencies from the All of Us Research program, PennMedicine BioBank (PMBB) and UKBB 500k datasets. We found that analyzing NAT2 diplotypes from phased data provides critical information for algorithms designed to predict diplotypes from unphased data. We observed that NAT2*5 , *6 , and *4 were the most common star alleles in that order, and the top 11 most frequent NAT2 star alleles were the same across all biobanks. However, differences in star allele frequencies across biogeographical populations were observed. The largest difference led to a higher frequency of NAT2 poor metabolizer phenotypes as compared to rapid and intermediate metabolizer phenotypes in all global populations except in the EAS population, where NAT2 poor metabolizers were in the minority.
- Open Access
A collaborative submission model for building high-quality data resources at scale through partnership: lessons from single-cell genomics
Community data resources that aggregate datasets across studies are critical infrastructure for modern biomedical research, accelerating discovery, and rapidly-advancing Artificial Intelligence (AI) models place ever-greater demand on large, well-described data corpora. However, building these resources involves a fundamental tension: comprehensive metadata is imperative for reuse, yet capturing this information systematically requires substantial effort that limits growth. We detail how CZ CELLxGENE Discover has used a collaborative submission model, whereby data contributors partner with dedicated resource curators, to become a large, widely used single-cell genomics resource for diverse analytical applications including AI model development and integrative analysis. This partnership leverages contributors’ intimate study knowledge and curators’ focus on data reuse and expertise in standardization to improve data quality, metadata accuracy, and richness. This is achieved by motivating researcher participation through tangible benefits while minimizing submission burden. We contrast this collaborative model with contributor-driven and resource-driven approaches, highlighting tradeoffs in scalability, consistency across submissions, and quality assurance. The principles and practices we describe provide a framework for building high-quality community data resources across diverse biological data types.
Open AccessA collaborative submission model for building high-quality data resources at scale through partnership: lessons from single-cell genomics
Community data resources that aggregate datasets across studies are critical infrastructure for modern biomedical research, accelerating discovery, and rapidly-advancing Artificial Intelligence (AI) models place ever-greater demand on large, well-described data corpora. However, building these resources involves a fundamental tension: comprehensive metadata is imperative for reuse, yet capturing this information systematically requires substantial effort that limits growth. We detail how CZ CELLxGENE Discover has used a collaborative submission model, whereby data contributors partner with dedicated resource curators, to become a large, widely used single-cell genomics resource for diverse analytical applications including AI model development and integrative analysis. This partnership leverages contributors’ intimate study knowledge and curators’ focus on data reuse and expertise in standardization to improve data quality, metadata accuracy, and richness. This is achieved by motivating researcher participation through tangible benefits while minimizing submission burden. We contrast this collaborative model with contributor-driven and resource-driven approaches, highlighting tradeoffs in scalability, consistency across submissions, and quality assurance. The principles and practices we describe provide a framework for building high-quality community data resources across diverse biological data types.
- Open Access
- 16 April 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (2) , 313-323
PharmVar GeneFocus: CYP1A2 —Clinical Impact, Genetic Variation, and Updated Nomenclature
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines. The activity of CYP1A2 varies significantly among individuals due to genetic and non‐genetic factors. This GeneFocus paper offers an overview of the functional significance of CYP1A2 in drug metabolism, CYP1A2 genetic variation, and presents the updated PharmVar star allele‐based nomenclature for CYP1A2 . Updates include revisions to previously defined star alleles to align with PharmVar standards, as well as the addition of novel star alleles, providing the pharmacogenetic community with a more comprehensive and high‐quality catalog of CYP1A2 genetic variation. We highlight that the common ‐163C>A (rs762551) variant, which previously defined CYP1A2*1F , is now the sole core variant for a newly established group of CYP1A2*30 alleles. Furthermore, the ‐163C>A variant, which has been associated with increased expression levels in smokers, has been found on various haplotypes in combination with one or more amino acid changing variants, each of which was assigned a unique star number (e.g., CYP1A2*13 , *21 , *24 , and *31 ). While all alleles containing ‐163C>A may have increased expression levels in smokers, it remains unknown whether the presence of one or more amino acids negates the effect of increased expression levels on CYP1A2 activity. Systematic nomenclature that comprehensively describes CYP1A2 variability is essential for future research aimed at assessing the relationship between CYP1A2 variation, drug metabolism, and the clinical utility of CYP1A2 pharmacogenetic testing.
- 16 April 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (2) , 313-323
Open AccessPharmVar GeneFocus: CYP1A2 —Clinical Impact, Genetic Variation, and Updated Nomenclature
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines. The activity of CYP1A2 varies significantly among individuals due to genetic and non‐genetic factors. This GeneFocus paper offers an overview of the functional significance of CYP1A2 in drug metabolism, CYP1A2 genetic variation, and presents the updated PharmVar star allele‐based nomenclature for CYP1A2 . Updates include revisions to previously defined star alleles to align with PharmVar standards, as well as the addition of novel star alleles, providing the pharmacogenetic community with a more comprehensive and high‐quality catalog of CYP1A2 genetic variation. We highlight that the common ‐163C>A (rs762551) variant, which previously defined CYP1A2*1F , is now the sole core variant for a newly established group of CYP1A2*30 alleles. Furthermore, the ‐163C>A variant, which has been associated with increased expression levels in smokers, has been found on various haplotypes in combination with one or more amino acid changing variants, each of which was assigned a unique star number (e.g., CYP1A2*13 , *21 , *24 , and *31 ). While all alleles containing ‐163C>A may have increased expression levels in smokers, it remains unknown whether the presence of one or more amino acids negates the effect of increased expression levels on CYP1A2 activity. Systematic nomenclature that comprehensively describes CYP1A2 variability is essential for future research aimed at assessing the relationship between CYP1A2 variation, drug metabolism, and the clinical utility of CYP1A2 pharmacogenetic testing.
- Open Access
- 14 April 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (2) , 387-393
Clinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for CYP2D6 Genotype and Use of 5‐ HT 3 Receptor Antagonists: 2026 Update
5‐hydroxytryptamine type 3 (5‐HT 3 ) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT 3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies. CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5‐HT 3 receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457 ).
- 14 April 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (2) , 387-393
Open AccessClinical Pharmacogenetics Implementation Consortium ( CPIC ) Guideline for CYP2D6 Genotype and Use of 5‐ HT 3 Receptor Antagonists: 2026 Update
5‐hydroxytryptamine type 3 (5‐HT 3 ) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT 3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies. CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5‐HT 3 receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457 ).
- Top Cited PapersOpen Access
- 31 January 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 916-927
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update
Thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard doses of thiopurines. Genetic variants in these genes are present in all world populations; however, their frequency varies by ancestry. In this updated guideline, we provide recommendations for adjusting starting doses of mercaptopurine, thioguanine, and azathioprine based on TPMT and NUDT15 genotypes, including for individuals with variants in both genes (updates on www.clinpgx.org ).
- 31 January 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 916-927
Top Cited PapersOpen AccessClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update
Thiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard doses of thiopurines. Genetic variants in these genes are present in all world populations; however, their frequency varies by ancestry. In this updated guideline, we provide recommendations for adjusting starting doses of mercaptopurine, thioguanine, and azathioprine based on TPMT and NUDT15 genotypes, including for individuals with variants in both genes (updates on www.clinpgx.org ).
- Open Access
- 23 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 859-871
PharmVar GeneFocus : NAT2 — Genetic Variation and Updated Nomenclature
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human N‐acetyltransferase 2 ( NAT2) gene. NAT2 metabolizes several clinically used drugs including isoniazid, hydralazine, amifampridine, procainamide, and sulfonamides such as dapsone, and also some highly carcinogenic arylamines. Systematic nomenclature describing NAT2 variation is essential for pharmacogenetic testing, genotype interpretation, and translation to phenotype in research and clinical settings. This GeneFocus provides an overview of NAT2 variation and describes important changes to its star allele‐based nomenclature that were made as it was transitioned to PharmVar in March 2024. We also highlight and discuss challenges regarding the characterization of allelic variation and determination of allele frequencies across world populations. The “new” NAT2 PharmVar nomenclature is utilized by ClinPGx (formerly PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
- 23 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 859-871
Open AccessPharmVar GeneFocus : NAT2 — Genetic Variation and Updated Nomenclature
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human N‐acetyltransferase 2 ( NAT2) gene. NAT2 metabolizes several clinically used drugs including isoniazid, hydralazine, amifampridine, procainamide, and sulfonamides such as dapsone, and also some highly carcinogenic arylamines. Systematic nomenclature describing NAT2 variation is essential for pharmacogenetic testing, genotype interpretation, and translation to phenotype in research and clinical settings. This GeneFocus provides an overview of NAT2 variation and describes important changes to its star allele‐based nomenclature that were made as it was transitioned to PharmVar in March 2024. We also highlight and discuss challenges regarding the characterization of allelic variation and determination of allele frequencies across world populations. The “new” NAT2 PharmVar nomenclature is utilized by ClinPGx (formerly PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
- Open Access
- 19 September 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (6) , 1430-1436
Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as “slow acetylators”) are predicted to have increased plasma hydralazine concentrations compared with NAT2 rapid and intermediate metabolizers (historically referred to as “rapid acetylators” and “intermediate acetylators,” respectively), which may lead to both increased clinical efficacy and adverse effects, including drug‐induced systemic lupus erythematosus. This guideline summarizes the evidence from the literature relevant to NAT2 /hydralazine and provides recommendations for hydralazine prescribing based on NAT2 genotype‐predicted acetylator phenotype (updates at www.cpicpgx.org ).
- 19 September 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (6) , 1430-1436
Open AccessClinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy
Hydralazine is a vasodilator typically used in the treatment of resistant hypertension and heart failure. N‐acetyltransferase 2 (NAT2) catalyzes the metabolism of hydralazine into inactive metabolites. NAT2 poor metabolizers (historically referred to as “slow acetylators”) are predicted to have increased plasma hydralazine concentrations compared with NAT2 rapid and intermediate metabolizers (historically referred to as “rapid acetylators” and “intermediate acetylators,” respectively), which may lead to both increased clinical efficacy and adverse effects, including drug‐induced systemic lupus erythematosus. This guideline summarizes the evidence from the literature relevant to NAT2 /hydralazine and provides recommendations for hydralazine prescribing based on NAT2 genotype‐predicted acetylator phenotype (updates at www.cpicpgx.org ).
- 18 July 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (6) , 1512-1522
Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium ( CPIC )
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has advanced clinical pharmacogenomics since 2009 by developing freely available, evidence‐based gene/drug guidelines. Covering 34 genes and 164 drugs, CPIC guidelines have become the global standard for translating pharmacogenomic test results into actionable prescribing decisions. This paper summarizes data highlighting CPIC’s pivotal role in accelerating the global adoption of pharmacogenomics and establishing itself as the leading resource for clinical implementation. To assess CPIC’s growth and impact, we analyzed member demographics, guideline characteristics, author composition, bibliometric data, database/API usage, and real‐world implementation using internal tracking, external databases (Scopus, iCite), website analytics, PubMed review (2019–2024), and CPIC member surveys (2012, 2024). CPIC has 28 active guidelines with international authorship and widespread adoption, garnering over 10,000 citations and 1.4 million views. Robust implementation is evident, with 85% of PubMed‐indexed pharmacogenomic implementation studies referencing CPIC guidelines. Additionally, 128 healthcare institutions and 40 commercial laboratories report using CPIC content. The CPIC API supports over 80,000 monthly queries, increasingly integrated into EHRs, including Epic’s foundational genomics module. Member surveys show a shift from scientific evidence concerns to practical barriers like clinician education, reimbursement, and EHR integration. CPIC has evolved from a guideline development initiative into a global leader in pharmacogenomics implementation, fostering collaboration, standardization, and sustainable integration into diverse healthcare settings.
- 18 July 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (6) , 1512-1522
Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium ( CPIC )
The Clinical Pharmacogenetics Implementation Consortium (CPIC) has advanced clinical pharmacogenomics since 2009 by developing freely available, evidence‐based gene/drug guidelines. Covering 34 genes and 164 drugs, CPIC guidelines have become the global standard for translating pharmacogenomic test results into actionable prescribing decisions. This paper summarizes data highlighting CPIC’s pivotal role in accelerating the global adoption of pharmacogenomics and establishing itself as the leading resource for clinical implementation. To assess CPIC’s growth and impact, we analyzed member demographics, guideline characteristics, author composition, bibliometric data, database/API usage, and real‐world implementation using internal tracking, external databases (Scopus, iCite), website analytics, PubMed review (2019–2024), and CPIC member surveys (2012, 2024). CPIC has 28 active guidelines with international authorship and widespread adoption, garnering over 10,000 citations and 1.4 million views. Robust implementation is evident, with 85% of PubMed‐indexed pharmacogenomic implementation studies referencing CPIC guidelines. Additionally, 128 healthcare institutions and 40 commercial laboratories report using CPIC content. The CPIC API supports over 80,000 monthly queries, increasingly integrated into EHRs, including Epic’s foundational genomics module. Member surveys show a shift from scientific evidence concerns to practical barriers like clinician education, reimbursement, and EHR integration. CPIC has evolved from a guideline development initiative into a global leader in pharmacogenomics implementation, fostering collaboration, standardization, and sustainable integration into diverse healthcare settings.
- 15 July 2025
- Published by Elsevier in Genetics in Medicine
- Vol. 27 (10) , 101529
Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities
- 15 July 2025
- Published by Elsevier in Genetics in Medicine
- Vol. 27 (10) , 101529
Toward an integrated resource for pharmacogenomics (PGx): Survey findings from the genomic medicine communities
- Open Access
- 27 January 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (5) , 1313-1324
Investigation of Genomic and Transcriptomic Risk Factors of Clopidogrel Response in African Americans
Clopidogrel, an anti‐platelet drug, is used to prevent thrombosis after percutaneous coronary intervention. Clopidogrel resistance results in recurring ischemic events, with African Americans (AA) suffering disproportionately. The aim of this study was to discover novel biomarkers of clopidogrel resistance in African Americans using genome and transcriptome data. We conducted a genome‐wide association study (GWAS), including local ancestry adjustment, in 141 AA on clopidogrel to identify genetic associations with high on‐treatment platelet reactivity (HTPR), with validation of genome‐wide significant and suggestive loci in an independent cohort of AA clopidogrel patients (N = 823) from the Million Veteran's Program (MVP) along with in vitro functional analysis. We performed differential gene expression (DGE) analysis in whole blood to identify transcriptomic predictors of response, followed by functional validation in MEG‐01 cells. GWAS identified one signal on Chromosome 7 as significantly associated with increasing risk of HTPR. The lead single‐nucleotide polymorphism (SNP), rs7807369, within thrombospondin 7A (THSD7A) was associated with an increased risk of HTPR (odds ratio (OR) = 4.02, P = 4.56 × 10−9). Higher THSD7A gene expression was associated with HTPR in an independent cohort of clopidogrel‐treated patients (P = 0.004) and carrying a risk allele showed increased gene expression in primary human endothelial cells. Notably, the CYP2C19*2 variants showed no association with clopidogrel response in the discovery or MVP cohorts. DGE analysis identified an association with decreased LAIR1 and AP3B2 expression to HTPR. LAIR1 knockdown in MEG‐01 cells resulted in increased expression of SYK and AKT1, suggesting an inhibitory role of LAIR1 in the Glycoprotein VI pathway. In summary, these findings suggest that other variants and genes outside of CYP2C19 star alleles play an important role in clopidogrel response in AA.
- 27 January 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (5) , 1313-1324
Open AccessInvestigation of Genomic and Transcriptomic Risk Factors of Clopidogrel Response in African Americans
Clopidogrel, an anti‐platelet drug, is used to prevent thrombosis after percutaneous coronary intervention. Clopidogrel resistance results in recurring ischemic events, with African Americans (AA) suffering disproportionately. The aim of this study was to discover novel biomarkers of clopidogrel resistance in African Americans using genome and transcriptome data. We conducted a genome‐wide association study (GWAS), including local ancestry adjustment, in 141 AA on clopidogrel to identify genetic associations with high on‐treatment platelet reactivity (HTPR), with validation of genome‐wide significant and suggestive loci in an independent cohort of AA clopidogrel patients (N = 823) from the Million Veteran's Program (MVP) along with in vitro functional analysis. We performed differential gene expression (DGE) analysis in whole blood to identify transcriptomic predictors of response, followed by functional validation in MEG‐01 cells. GWAS identified one signal on Chromosome 7 as significantly associated with increasing risk of HTPR. The lead single‐nucleotide polymorphism (SNP), rs7807369, within thrombospondin 7A (THSD7A) was associated with an increased risk of HTPR (odds ratio (OR) = 4.02, P = 4.56 × 10−9). Higher THSD7A gene expression was associated with HTPR in an independent cohort of clopidogrel‐treated patients (P = 0.004) and carrying a risk allele showed increased gene expression in primary human endothelial cells. Notably, the CYP2C19*2 variants showed no association with clopidogrel response in the discovery or MVP cohorts. DGE analysis identified an association with decreased LAIR1 and AP3B2 expression to HTPR. LAIR1 knockdown in MEG‐01 cells resulted in increased expression of SYK and AKT1, suggesting an inhibitory role of LAIR1 in the Glycoprotein VI pathway. In summary, these findings suggest that other variants and genes outside of CYP2C19 star alleles play an important role in clopidogrel response in AA.